Tooth Stem Cells Take a Bite Off T Cell Proliferation
Ding et al. Cells Tissues Organs., January 14, 2010
Mesenchymal stem cells are known classically to be capable
of generating bone, fat, and cartilage tissues, and more recently have been
demonstrated to have ability to become brain cells, liver cells, pancreas cells,
and muscle cells. The original studies on mesenchymal stem cells used bone
marrow as the originating tissue, with subsequent studies having identified
these cells in fat, muscle, and menstrual blood. For a description of
mesenchymal stem cells, please view this video
http://www.youtube.com/watch?v=8WzalE5hLUs.
Recently mesenchymal stem cells have been identified in
deciduous (baby) teeth, as well as wisdom teeth. Given the ease of tooth
collection several companies have started banking tooth derived stem cells for
future use, in a similar manner to which cord blood cells are banked. Potential
uses of mesenchymal stem cells include regeneration of injured tissue. For
example the company Osiris has recently released clinical trial data
demonstrating that intravenous administration of bone marrow derived mesenchymal
stem cells results in patient improvements after heart attacks. Additionally,
because these cells produce immune modulatory factors, mesenchymal stem cells
have been used with success in treatment of autoimmune conditions in mice and
man.
Unfortunately the major work on mesenchymal stem cells has
focused on cells derived from the bone marrow, with some studies discussing
cells from the cord blood. Despite ease of tissue acquisition, relatively
little is known about tooth derived mesenchymal stem cells. A recent paper (Ding
et al. Suppression of T Cell Proliferation by Root Apical Papilla Stem Cells in
vitro. Cells Tissues Organs. 2010 Jan 14) examined the immunological
properties of these cells using an in vitro system.
The investigators grew mesenchymal stem cells from teeth of
pigs in order to generate a source of cells that can be used for future in vivo
experiments. The cells had some characteristics of bone marrow derived
mesenchymal stem cells in that they expressed low concentrations of the immune
stimulatory molecule Swine Leukocyte Antigen (SLA) I, which is the porcine
equivalent of HLA I, as well as absence of SLA II.
Mixing of pig peripheral blood mononuclear cells with the
compound phytohemagluttanin is known to result in stimulation of proliferation
of the T cell component of the mononuclear cells. When these stimulated T cells
are placed in the presence of porcine mesenchymal stem cells, a dose dependent
suppression of proliferation was observed. This in vitro model of T cell
activation was also confirmed in a scenario where T cells were purposely mis-matched
antigenically with the mesenchymal stem cells and it was observed that the cells
did not stimulate T cell proliferation. Addition of mesenchymal stem cells to a
mixed lymphocyte reaction in which T cells are activated in response to other T
cells resulted in the inhibition of T cell proliferation.
Mechanistically it was determined that inhibition of T cell
proliferation was occurring through secretion of a soluble factor by the
mesenchymal stem cells that does not induce killing of the activated T cells.
This poses the question if the mesenchymal stem cells were not just inhibiting
proliferation but also activating T regulatory cells that are known to protect
against pathological autoimmunity. Previous studies have demonstrated that bone
marrow mesenchymal stem cells generate T regulatory cells (Di Ianni et al.
Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol. 2008
Mar;36(3):309-18). In fact, generation of T regulatory cells has been
described as one of the mechanisms in which stem cell therapy works against
rheumatoid arthritis
http://www.youtube.com/watch?v=NhNvy6YyLtc.
The ability to use stem cells to inhibit T cell responses
has many therapeutic applications. The current paper is one of the first to
demonstrate that tooth derived mesenchymal stem cells, like their cousins from
the fat and bone marrow, are capable of inhibiting immune responses that
previously were pathological.
|